News

CF Patients Voice Hopes and Expectations for Trikafta in Instagram Poll

A majority of cystic fibrosis patients who took part in an Instagram poll by Bionews Services said they would be interested in moving from current treatments to Trikafta (elexacaftor, tezacaftor, and ivacaftor), the newly approved and “next-generation” combination therapy by Vertex that is expected to treat 90% of all…

Cystic Fibrosis Foundation Applauds FDA Approval of Trikafta

The Cystic Fibrosis Foundation (CFF) is celebrating the United States Food and Drug Administration’s decision to approve Trikafta. The therapy — a triple combo based on elexacaftor, tezacaftor, and ivacaftor, which is being developed by Vertex Pharmaceuticals — was approved on Oct. 21 for people with cystic fibrosis (CF)…